• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cost-effectiveness of follow-up invasive coronary angiography after percutaneous coronary stenting: a real-world observational cohort study in Japan
Conclusions FUICA increased the costs but did not improve clinical benefits. Thus, FUICA is not economically more attractive than CF alone. Trial registration number UMIN000039768.
Source: BMJ Open - August 30, 2022 Category: General Medicine Authors: Shiina, T., Goto-Hirano, K., Takura, T., Daida, H. Tags: Open access, Health economics Source Type: research

Hospital costs associated with intraoperative hypotension among non-cardiac surgical patients in the US: a simulation model.
CONCLUSIONS: The model results suggest improved intraoperative hypotension control in a hospital with annual volume 10,000 non-cardiac surgical patients is associated with mean cost reductions ranging from $1.2 to $4.6 million per year. Since the magnitude of the RCT mean estimate is similar to the unadjusted observational model, the institutional costs are likely at the upper end of this range. PMID: 30838899 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - March 7, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Vitamin C supplementation for the primary prevention of cardiovascular disease.
CONCLUSIONS: Currently, there is no evidence to suggest that vitamin C supplementation reduces the risk of CVD in healthy participants and those at increased risk of CVD, but current evidence is limited to one trial of middle-aged and older male physicians from the USA. There is limited low- and very low-quality evidence currently on the effect of vitamin C supplementation and risk of CVD risk factors. PMID: 28301692 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - March 15, 2017 Category: Journals (General) Authors: Al-Khudairy L, Flowers N, Wheelhouse R, Ghannam O, Hartley L, Stranges S, Rees K Tags: Cochrane Database Syst Rev Source Type: research

4 Key Insights When Raising Money for Your Medtech Startup: Interview with Bruce Shook, CEO of Intact Vascular
Welcome to the Medsider interview series, a regular feature at MassDevice. All interviews are conducted by Scott Nelson, Founder of Medsider and Group Director for WCG. We hope you enjoy them! Bruce Shook joined Intact Vascular in 2014 as President and CEO. A highly-experienced, medical device executive with more than 30 years of industry experience, Bruce was previously Co-founder, Director, President, and CEO of Neuronetics, which is a privately held medical device company that markets a non-invasive brain stimulation technology for the treatment of depression. Previously, Shook was Co-founder, Director, President, an...
Source: Mass Device - February 27, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Blog medsider Source Type: news

Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK
Conclusions Revascularisation and myocardial infarction were associated with the highest incremental costs following a CV event. On the basis of real-world data, the economic burden of CV events in the UK is substantial, particularly among those with greater comorbidity burden.
Source: BMJ Open - August 4, 2016 Category: Journals (General) Authors: Danese, M. D., Gleeson, M., Kutikova, L., Griffiths, R. I., Azough, A., Khunti, K., Seshasai, S. R. K., Ray, K. K. Tags: Open access, Cardiovascular medicine, Health economics, Health services research Source Type: research

Right care and high-value cardiology: doctors' responsibilities to the patient and the population
Significant advances in cardiovascular care, developed over the past three decades, are now routine treatment for people with heart disease—for example, primary angioplasty for acute ST elevation myocardial infarction is available to over 70% of the UK population, resynchronisation and defibrillator pacing devices are options for those with advanced heart failure, and drug therapies such as statins for secondary prevention have made significant impacts in reducing cardiovascular mortality in the past 50 years. Today, patients with cardiovascular disease can expect a better quality of life and greater longevity t...
Source: Postgraduate Medical Journal - August 24, 2015 Category: Journals (General) Authors: Malhotra, A., Apps, A., Saini, V., Gray, M. Tags: Patients, General practice / family medicine, Drugs: cardiovascular system, Stroke, Interventional cardiology, Ischaemic heart disease, Radiology, Clinical diagnostic tests, Cardiothoracic surgery, Vascular surgery, Epidemiology, Health economics Editor Source Type: research

Bypass surgery is more cost-effective than percutaneous coronary interventions for most patients with multivessel or left main coronary artery disease
Commentary on: Cohen DJ, Osnabrugge RL, Magnuson EA, et al; SYNTAX Trial Investigators. Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation 2014;130:1146–57. Context The SYNTAX (SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery) trial compared outcomes of percutaneous coronary intervention (PCI) with drug eluting stents (DES) and coronary a...
Source: Evidence-Based Medicine - March 17, 2015 Category: Internal Medicine Authors: Agarwal, S., Kapadia, S. R. Tags: Health policy, Drugs: cardiovascular system, Stroke, Interventional cardiology, Ischaemic heart disease, Health economics, Health service research Economic analysis Source Type: research

Cost‐effectiveness of percutaneous coronary intervention with drug‐eluting stents in patients with multivessel coronary artery disease compared to coronary artery bypass surgery 5 years after intervention
Conclusions. Cost‐effectiveness analysis of DES‐PCI vs. CABG demonstrated that CABG is the most effective, but most costly, treatment for preventing MACCE in patients with multivessel disease. © 2013 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - January 9, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Lisa Krenn, Christoph Kopp, Dietmar Glogar, Irene M Lang, Georg Delle‐Karth, Thomas Neunteufl, Gerhard Kreiner, Alexandra Kaider, Jutta Bergler‐Klein, Aliasghar Khorsand, Maryam Nikfardjam, Günther Laufer, Gerald Maurer, Mariann Gyöngyösi Tags: Research Article Source Type: research